COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $250 million in 67 projects around the world.











focused on new classes


The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More

Spotlight on Science

T2 Biosystems’ diagnostic panel can identify superbug drug resistance days faster than current methods

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.


UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners




Basel, Switzerland

BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics


  • 08.11.2020  |  CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics to treat multidrug-resistant bacterial infections full release

  • 07.07.2020  |  CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause life-threatening pneumonia and other deadly infections full release

  • 06.30.2020  |  CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics derived from bacteriophages to kill superbugs and prevent deadly infections in transplant patients full release

See All News

In The News

  • 08.12.2020  |  Pharmaceutical firms commit US$1 billion to antibiotic development full story

  • 08.12.2020  |  We need new antimicrobials to prevent the next infectious disease crisis full story

  • 08.09.2020  |  It is time to fix the antibiotic market full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.